Metagenomi Therapeutics, Inc. - 8-K Filing
Metagenomi Therapeutics reported $140.2 million in cash as of March 31, 2026, with a runway through Q4 2027. R&D expenses were $19.3 million for the quarter ended March 31, down from $25.1 million year-over-year, while G&A expenses were $6.5 million versus $6.8 million in the prior year period. The company is on track to submit an IND application for its lead program MGX-001 by Q4 2026 and plans clinical trials starting in 2027. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $MGX